Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
PTGX
Home
/
PTGX

NASDAQ
$143.79
$143.79

Overview

Price performance
Low
$138.62
High
$145.61
Market open. Last updated: Nov 4, 2026, 7:07 PM UTC
$
143.79
3.55 (2.53%)
Average, 50 days
$142.34
$117.19
Open
$145.61
Previous close
$140.24
52-week high
$160.81
Aug 19, 2026 (3 months ago)
52-week low
$75.55
Nov 5, 2025 (13 months ago)
90.32%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
9.30B
Volume
228 121
Total Return (3M)
5.78%
Total Return (1Y)
87.78%
19.34
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
protagonist-inc.com
Socials
About
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Frequently asked questions

PTGX · Protagonist Therapeutics, Inc.

01What is Protagonist Therapeutics, Inc. stock price today?

The current price of PTGX is $143.79 — it has increased by 2.53% since the previous close. Data as of Nov 4, 2026.

02Is Protagonist Therapeutics, Inc. stock price growing?

PTGX is down 0.48% over the past week, up 2.57% over the past month and up 87.78% over the past year. The price is above its 200-day moving average of $117.19.

03What is PTGX stock forecast?

Analysts' average 12-month price target for PTGX is $177.25, which implies 23.27% upside from the current price. Individual estimates range from $165.00 to $190.00.

04What do analysts say about PTGX stock?

Of the 14 analysts covering Protagonist Therapeutics, Inc., 3 rate it a strong buy and 11 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

05What is Protagonist Therapeutics, Inc. market cap?

Protagonist Therapeutics, Inc. has a market capitalization of $9.3B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

06What were Protagonist Therapeutics, Inc. earnings last quarter?

In its most recent quarterly report, Protagonist Therapeutics, Inc. posted earnings of $2.29 per share against an estimate of $2.23, beating expectations by 2.69%. Upcoming reports are listed in the earnings calendar.

07What is Protagonist Therapeutics, Inc. revenue for the last quarter?

Protagonist Therapeutics, Inc. reported revenue of $213.48M in its most recent quarter, which has increased by 3,749.17% compared with the same quarter a year earlier. Analysts had expected $198.66M.

08Does Protagonist Therapeutics, Inc. pay dividends?

Protagonist Therapeutics, Inc. has not paid any dividends over the past year.

09Who are Protagonist Therapeutics, Inc. competitors?

Companies most comparable to Protagonist Therapeutics, Inc. include Spyre Therapeutics, Inc., Immunovant, Inc., Disc Medicine, Inc., AnaptysBio, Inc. and Odyssey Therapeutics, Inc.

10How volatile is PTGX stock?

In the latest trading session PTGX moved between $138.62 and $145.61, a range of 4.86% of its current price.

11Should I invest in Protagonist Therapeutics, Inc. stock?

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Protagonist Therapeutics, Inc. shows a strong buy rating today and a strong buy rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Protagonist Therapeutics, Inc. is buy. Technical ratings are indicators, not investment advice.

12What are PTGX stock 52-week high and low?

Over the past 52 weeks PTGX has traded between $75.55 and $160.81. The current price is 10.58% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.